{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T19:05:20Z","timestamp":1780427120445,"version":"3.54.1"},"reference-count":16,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100000291","name":"Kidney Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000291","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012357","name":"LifeArc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012357","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002927","name":"Addenbrooke's Charitable Trust, Cambridge University Hospitals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002927","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis &amp; Rheumatology"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Ear, nose, and throat (ENT) manifestations are common in antineutrophil cytoplasmic antibody (ANCA)\u2013associated vasculitis (AAV). There is an unmet need for drugs to target these manifestations. Granuloma formation is characteristic of proteinase 3 (PR3)\u2013AAV. In a zebrafish model, niclosamide inhibits PR3\u2010induced granuloma formation. We hypothesized that intranasal niclosamide would reduce AAV\u2010associated ENT symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PROTECT\u2010V was a randomized, double\u2010blind, placebo\u2010controlled platform trial evaluating pre\u2010exposure prophylaxis agents against COVID\u201019 infection. This subanalysis includes patients from a single center with AAV, enrolled into the intranasal niclosamide arm. Clinical data were retrospectively collected for nine months before, during, and nine months after treatment. Researchers were blinded to treatment allocation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 32 (14 niclosamide; 18 placebo) patients, 11 (34%) were female; the median age was 69 (interquartile range [IQR] 59\u201375) years. Median prior AAV disease duration was 5.4 (IQR 1.9\u201313.1) years; 19 (59%) had active disease in the year before treatment. Median treatment exposure was 200 (IQR 109\u2013251) days. During treatment, ENT symptoms were identified in 1 of 14 (7%) of the niclosamide group compared with 7 of 18 (39%) of the placebo group (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.04). No significant difference between groups was found in the nine months before or after treatment. Among PR3\u2010ANCA\u2013positive patients, 0 of 10 in the niclosamide group compared to 5 of 9 (56%) in the placebo group had ENT symptoms during treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      These data are a signal of potential clinical effect on ENT manifestations in AAV. They support a role for the IL\u20106 and\n                      <jats:italic>STAT3<\/jats:italic>\n                      pathway in AAV; intranasal niclosamide or other drug candidates in this pathway warrant further evaluation.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/art.70061","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T03:41:17Z","timestamp":1770608477000},"page":"970-975","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Effect of Intranasal Niclosamide on Nasal Symptoms in Patients with Antineutrophil Cytoplasmic Antibody\u2013Associated Vasculitis"],"prefix":"10.1002","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4337-8268","authenticated-orcid":false,"given":"Benjamin","family":"Lim","sequence":"first","affiliation":[{"name":"University Hospitals of Leicester NHS Trust  Leicester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendi","family":"Qian","sequence":"additional","affiliation":[{"name":"University of Cambridge  Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Dowling","sequence":"additional","affiliation":[{"name":"Cambridge University Hospitals NHS Foundation Trust  Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Salama","sequence":"additional","affiliation":[{"name":"University College London, Centre for Kidney and Bladder Health, Royal Free Hospital  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rona M","family":"Smith","sequence":"additional","affiliation":[{"name":"University of Cambridge  Cambridge UK"},{"name":"Cambridge University Hospitals NHS Foundation Trust  Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-018-4019-0"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaf240"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.11075"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41773"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.10.008"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223764"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1684\/ecn.2019.0439"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.07.001"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2021-221800"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12227059"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1072598"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1021\/ml100146z"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-025-10584-4"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221795"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41120-023-00072-x"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2015.02.002"}],"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.70061","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/art.70061","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.70061","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T07:16:01Z","timestamp":1775546161000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.70061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1002\/art.70061"],"URL":"https:\/\/doi.org\/10.1002\/art.70061","archive":["Portico"],"relation":{},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"assertion":[{"value":"2025-07-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}